Drugs / MGS-0210
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01548703 | Feb → Apr 2012 | — | BrainCells Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01546051 | Oct 2011 → Jan 2012 | — | BrainCells Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGS-0210 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594408 ↗ |
| Known as | BCI-838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01548703 ↗ |
| Modality | Small molecule | — CHEMBL4594408 ↗ |
| Route | Oral | “BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design” NCT01546051 ↗ |